Potential MiRNA-target Interactions for the Screening of Gastric Carcinoma Development in Gastric Adenoma/dysplasia

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2018 May 5

PMID 29725252

Citations 15

Authors

Yu Jin Kim

Ki-Chul Hwang

Sang Woo Kim

Yong Chan Lee

Affiliations

Soon will be listed here.

Abstract

Although miRNA markers have been identified for the pathological development of gastric adenocarcinoma (GAC), the underlying molecule mechanism are still not fully understood. Moreover, some gastric adenoma/dysplasia may progress to GAC. In this study, the miRNA expression profiles in normal and paired low-/high-grade dysplasia were analyzed using Affymetrix Gene-Chip miRNA arrays. Of the total 2578 mature miRNA probe sets, ~1600 showed positive signals when the between normal and paired low-/high-grade dysplasia were compared. To verify the miRNA expression, qRT-PCR analysis was performed to quantify the expression of altered miRNAs between normal and paired low-/high-grade dysplasia. The analysis revealed that hsa-miR-421, hsa-miR-29b-1-5p, and hsa-miR-27b-5p were overexpressed in gastric low-/high-grade dysplasia and that based on these miRNA-target interactions, FBXO11 and CREBZF could be considered convincing markers for gastric cancer (GC) progression. Thus, we identified three miRNAs (hsa-miR-421, hsa-miR-29b-1-5p, and hsa-miR-27b-5p) with two mRNAs (FBXO11 and CREBZF) that might play an important role in the GC development from premalignant adenomas. Furthermore, these two target mRNAs and three miRNAs were predicted to be potential biomarkers for the progression of GC by miRNA-target interaction analysis.

Citing Articles

Downregulation of cancer-associated fibroblast exosome-derived miR-29b-1-5p restrains vasculogenic mimicry and apoptosis while accelerating migration and invasion of gastric cancer cells via immunoglobulin domain-containing 1/zonula occluden-1 axis.

Wu C, Li D, Cheng X, Gu H, Qian Y, Feng L Cell Cycle. 2023; 22(17):1807-1826.

PMID: 37587724 PMC: 10599179. DOI: 10.1080/15384101.2023.2231740.

Advances in our understanding of the molecular pathogenesis of necrotizing enterocolitis.

Cai X, Golubkova A, Hunter C BMC Pediatr. 2022; 22(1):225.

PMID: 35468817 PMC: 9036771. DOI: 10.1186/s12887-022-03277-3.

Mangiferin Inhibits Human Lung Adenocarcinoma by Suppressing MiR-27b and MiR-92a.

Chi X, Meng J, Lin C, Su Q, Qin Y, Wei R Evid Based Complement Alternat Med. 2021; 2021:2822950.

PMID: 34335801 PMC: 8292060. DOI: 10.1155/2021/2822950.

A stable gene set for prediction of prognosis and efficacy of chemotherapy in gastric cancer.

Wu R, Guo S, Lai S, Pan G, Zhang L, Liu H BMC Cancer. 2021; 21(1):684.

PMID: 34112138 PMC: 8194165. DOI: 10.1186/s12885-021-08444-w.

Biased Influences of Low Tumor Purity on Mutation Detection in Cancer.

Cheng J, He J, Wang S, Zhao Z, Yan H, Guan Q Front Mol Biosci. 2021; 7:533196.

PMID: 33425983 PMC: 7785586. DOI: 10.3389/fmolb.2020.533196.

References

Yamada H, Ikegami M, Shimoda T, Takagi N, Maruyama M . Long-term follow-up study of gastric adenoma/dysplasia. Endoscopy. 2004; 36(5):390-6. DOI: 10.1055/s-2004-814330. View

Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D . Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009; 24(4):652-7. DOI: 10.1111/j.1440-1746.2008.05666.x. View

Sipponen P . Gastric dysplasia. Curr Top Pathol. 1990; 81:61-76. DOI: 10.1007/978-3-642-74662-8_3. View

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10):997-1006. DOI: 10.1038/cr.2008.282. View

Abbas T, Keaton M, Dutta A . Regulation of TGF-β signaling, exit from the cell cycle, and cellular migration through cullin cross-regulation: SCF-FBXO11 turns off CRL4-Cdt2. Cell Cycle. 2013; 12(14):2175-82. PMC: 3755067. DOI: 10.4161/cc.25314. View

Zhu J, Zheng Z, Wang J, Sun J, Wang P, Cheng X . Different miRNA expression profiles between human breast cancer tumors and serum. Front Genet. 2014; 5:149. PMC: 4033838. DOI: 10.3389/fgene.2014.00149. View

Shukla G, Singh J, Barik S . MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol. 2012; 3(3):83-92. PMC: 3315687. View

Zhang X, Peng Y, Jin Z, Huang W, Cheng Y, Liu Y . Integrated miRNA profiling and bioinformatics analyses reveal potential causative miRNAs in gastric adenocarcinoma. Oncotarget. 2015; 6(32):32878-89. PMC: 4741736. DOI: 10.18632/oncotarget.5419. View

Rugge M, Farinati F, Baffa R, Sonego F, Di Mario F, Leandro G . Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology. 1994; 107(5):1288-96. DOI: 10.1016/0016-5085(94)90529-0. View

10.

Taniyama D, Taniyama K, Kuraoka K, Zaitsu J, Saito A, Nakatsuka H . Long-term follow-up study of gastric adenoma; tumor-associated macrophages are associated to carcinoma development in gastric adenoma. Gastric Cancer. 2017; 20(6):929-939. DOI: 10.1007/s10120-017-0713-x. View

11.

Noguchi T, Toiyama Y, Kitajima T, Imaoka H, Hiro J, Saigusa S . miRNA-503 Promotes Tumor Progression and Is Associated with Early Recurrence and Poor Prognosis in Human Colorectal Cancer. Oncology. 2016; 90(4):221-31. DOI: 10.1159/000444493. View

12.

Abbas T, Mueller A, Shibata E, Keaton M, Rossi M, Dutta A . CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration. Mol Cell. 2013; 49(6):1147-58. PMC: 3615078. DOI: 10.1016/j.molcel.2013.02.003. View

13.

Wang Y, Tian Y . miRNA for diagnosis and clinical implications of human hepatocellular carcinoma. Hepatol Res. 2015; 46(1):89-99. DOI: 10.1111/hepr.12571. View

14.

Lu Y, Tang L, Zhang Q, Zhang Z, Wei W . MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9. Artif Cells Nanomed Biotechnol. 2017; 46(5):980-984. DOI: 10.1080/21691401.2017.1351983. View

15.

Cui L, Zhang X, Ye G, Zheng T, Song H, Deng H . Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer. 2013; 119(9):1618-26. DOI: 10.1002/cncr.27903. View

16.

Anauate A, Leal M, Wisnieski F, Santos L, Gigek C, Chen E . Identification of suitable reference genes for miRNA expression normalization in gastric cancer. Gene. 2017; 621:59-68. DOI: 10.1016/j.gene.2017.04.016. View

17.

Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H . Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer. 2012; 106(4):740-7. PMC: 3322946. DOI: 10.1038/bjc.2011.588. View

18.

Zhang S, Gao L, Thakur A, Shi P, Liu F, Feng J . miRNA-204 suppresses human non-small cell lung cancer by targeting ATF2. Tumour Biol. 2016; 37(8):11177-86. DOI: 10.1007/s13277-016-4906-4. View

19.

Abozeid M, Rosato A, Sommaggio R . Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. Biomed Res Int. 2017; 2017:5791262. PMC: 5525095. DOI: 10.1155/2017/5791262. View

20.

Lopez-Mateo I, Villaronga M, Llanos S, Belandia B . The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11(20):3887-95. PMC: 3495830. DOI: 10.4161/cc.22133. View